• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Plasma erythropoietin level and iron reserves in haemodialysis patients with and without acquired cystic kidney disease.

作者信息

Majdan M, Ksiazek A, Kozioł M, Spasiewicz D

机构信息

Department of Nephrology, Medical Academy, Lublin, Poland.

出版信息

Int Urol Nephrol. 1997;29(1):113-8. doi: 10.1007/BF02551426.

DOI:10.1007/BF02551426
PMID:9203047
Abstract

Concentration of erythropoietin (Epo) and iron reserves (IR) belong to the essential factors determining erythropoiesis in haemodialysis patients. Patients on dialysis with acquired kidney disease (ACKD+) can control anaemia better than patients without acquired kidney disease (ACKD-). Therefore we decided to check if plasma Epo levels and IR differ significantly in both groups of patients. Forty chronically haemodialyzed patients after ultrasound diagnosis were divided into 18 patients (45%) with ACKD+ and 22 (55%) without ACKD-. In both groups of patients we compared their plasma levels of Epo and IR. Plasma erythropoietin and ferritin levels were measured by enzymatic immunoassay. Iron reserves were estimated by the formula: IR = 400 x [ln (ferritin)-ln (50)]. In the ACKD+ group 72% of patients and in the ACKD- group 32% of patients did not require rHu Epo therapy. Plasma levels of erythropoietin and iron reserves did not differ significantly between ACKD+ and ACKD- patients. There must be also other factors than erythropoietin levels and iron reserves regulating erythropoiesis in these patients.

摘要

相似文献

1
Plasma erythropoietin level and iron reserves in haemodialysis patients with and without acquired cystic kidney disease.
Int Urol Nephrol. 1997;29(1):113-8. doi: 10.1007/BF02551426.
2
[Comparison of the ability to control anemia in patients on hemodialysis and peritoneal dialysis considering iron reserves and plasma erythropoietin].
Pol Arch Med Wewn. 1996 Apr;95(4):307-12.
3
Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.常规低剂量静脉铁剂治疗可改善血液透析患者对促红细胞生成素的反应。
Nephrol Dial Transplant. 1996 Jun;11(6):1079-83.
4
[Acquired cystic kidney disease (ACKD): experience of a dialysis center].[获得性囊性肾病(ACKD):一家透析中心的经验]
Arch Ital Urol Androl. 2000 Dec;72(4):221-4.
5
Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Nephron. 1996;73(3):425-9. doi: 10.1159/000189105.
6
Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin.
Am J Nephrol. 1991;11(1):12-5. doi: 10.1159/000168265.
7
Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients.多囊肾病患者与其他血液透析患者血清免疫反应性促红细胞生成素水平的比较。
Nephron. 1985;39(1):26-9. doi: 10.1159/000183332.
8
Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.血液透析患者和肾移植受者的血清促红细胞生成素水平及其与红细胞生成系统的相关性。
Transplant Proc. 2007 May;39(4):1051-3. doi: 10.1016/j.transproceed.2007.03.048.
9
Comparison of acquired cystic kidney disease between hemodialysis and continuous ambulatory peritoneal dialysis.血液透析与持续性非卧床腹膜透析患者获得性囊性肾病的比较。
Korean J Intern Med. 2000 Jan;15(1):51-5. doi: 10.3904/kjim.2000.15.1.51.
10
Erythropoietin concentrations and erythropoiesis in newborns suffering from renal agenesis and congenital kidney diseases.
Eur J Pediatr. 1996 Mar;155(3):185-8. doi: 10.1007/BF01953935.

引用本文的文献

1
Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients.
Int Urol Nephrol. 2001;33(3):541-6. doi: 10.1023/a:1019558511411.

本文引用的文献

1
Molecular biology of erythropoietin.促红细胞生成素的分子生物学
Kidney Int. 1993 Oct;44(4):887-904. doi: 10.1038/ki.1993.327.
2
Monitoring of iron requirements in renal patients on erythropoietin.对接受促红细胞生成素治疗的肾病患者铁需求的监测。
Nephrol Dial Transplant. 1993;8(9):846-53.
3
Erythropoiesis in dialysis patients with acquired cystic kidney disease. Collaborative Group of Nephrologists of the East of France.法国东部肾病学家协作组:获得性囊性肾病透析患者的红细胞生成
Nephron. 1994;66(1):119-20. doi: 10.1159/000187783.
4
[Comparison of clinical parameters of chronically hemodialyzed patients not requiring treatment with erythropoietin and patients treated with erythropoietin].[无需促红细胞生成素治疗的长期血液透析患者与接受促红细胞生成素治疗的患者的临床参数比较]
Pol Arch Med Wewn. 1994 Jun;91(6):461-6.
5
Hereditary and acquired cystic disease of the kidney.遗传性和获得性肾囊性疾病
Kidney Int. 1994 Oct;46(4):951-64. doi: 10.1038/ki.1994.354.
6
Sex differences in acquired cystic disease of the kidney on long-term dialysis.长期透析患者获得性肾囊肿疾病中的性别差异。
Nephron. 1985;39(4):336-40. doi: 10.1159/000183401.
7
Clinical characteristics and diagnostic considerations in acquired renal cystic disease.
Kidney Int. 1986 Nov;30(5):748-52. doi: 10.1038/ki.1986.251.
8
Cystic kidneys.多囊肾
Kidney Int. 1988 Feb;33(2):610-21. doi: 10.1038/ki.1988.41.
9
The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.
Kidney Int. 1989 Jan;35(1):134-48. doi: 10.1038/ki.1989.18.
10
Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin.
Am J Nephrol. 1991;11(1):12-5. doi: 10.1159/000168265.